EMERGE

Tiny Announces Definitive Agreement to acquire WholesalePet

Retrieved on: 
Wednesday, January 24, 2024

Tiny Ltd. (“Tiny” or the “Company”) (TSXV: TINY), a Canadian technology holding company, today announced that its private partnership Tiny Fund I, LP (the “Buyer”) has entered into a definitive agreement (the “Definitive Agreement”) to acquire Retail Store Networks, Inc (d/b/a WholesalePet.com) (“WSP”), a B2B marketplace for wholesale pet products from EMERGE US Holdings LLC (the “Seller”), a subsidiary of EMERGE Commerce Ltd. (“EMERGE”) (TSXV:ECOM).

Key Points: 
  • Tiny Ltd. (“Tiny” or the “Company”) (TSXV: TINY), a Canadian technology holding company, today announced that its private partnership Tiny Fund I, LP (the “Buyer”) has entered into a definitive agreement (the “Definitive Agreement”) to acquire Retail Store Networks, Inc (d/b/a WholesalePet.com) (“WSP”), a B2B marketplace for wholesale pet products from EMERGE US Holdings LLC (the “Seller”), a subsidiary of EMERGE Commerce Ltd. (“EMERGE”) (TSXV:ECOM).
  • WSP specializes in serving pet boutiques, pet stores, and pet service businesses, including pet boarding and grooming.
  • The platform enables thousands of independent pet retailers to purchase pet products from a diverse range of manufacturers and distributors.
  • “We are excited to partner with Tiny for the next stage of growth at WholesalePet,” said founder Robert Nelson.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Saturday, January 13, 2024

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Tuesday, January 9, 2024

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

EQS-News: Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Retrieved on: 
Thursday, December 21, 2023

The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product’s test report.

Key Points: 
  • The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product’s test report.
  • It was designed as a scalable, unbiased methodology to produce transparent algorithms from complex data, without any prior assumptions.
  • “The work Mainz Biomed is doing will be crucial to saving lives from a disease where mortality is driven by late detection.
  • As such, we are very pleased to have the opportunity to play an integral role in helping it develop the next generation of its pioneering products.”

ForwardLane's Generative AI Platform Selected for AWS Global Fintech Accelerator 2023

Retrieved on: 
Tuesday, November 14, 2023

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- ForwardLane, creators of EMERGE, an enterprise-ready generative AI platform, today announced its selection into the inaugural AWS NVIDIA Global Fintech Accelerator.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- ForwardLane, creators of EMERGE, an enterprise-ready generative AI platform, today announced its selection into the inaugural AWS NVIDIA Global Fintech Accelerator.
  • "We are thrilled to join the AWS Global Fintech Accelerator to accelerate our mission of democratizing access to data-driven insights," said Nathan Stevenson, CEO of ForwardLane.
  • "The AWS Global Fintech Accelerator will supercharge our exciting new Generative AI use cases, unlocking the hidden potential in enterprise data," said Stevenson.
  • "We look forward to collaborating with AWS, NVIDIA and partners to shape the future of generative AI."

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Retrieved on: 
Thursday, November 9, 2023

The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product’s test report.

Key Points: 
  • The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product’s test report.
  • It was designed as a scalable, unbiased methodology to produce transparent algorithms from complex data, without any prior assumptions.
  • “The work Mainz Biomed is doing will be crucial to saving lives from a disease where mortality is driven by late detection.
  • As such, we are very pleased to have the opportunity to play an integral role in helping it develop the next generation of its pioneering products.”

Kennametal Releases 2023 Environmental, Social and Governance (ESG) Report

Retrieved on: 
Tuesday, September 12, 2023

PITTSBURGH, Sept. 12, 2023 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) today announced that is has published its fiscal year 2023 Environmental, Social, Governance (ESG) report. The report outlines the company's continued progress in advancing its ESG strategy and the issues most important to stakeholders, including environmental, health and safety (EHS), employee engagement, workforce training and development, diversity and inclusion, community engagement and other material topics.

Key Points: 
  • PITTSBURGH, Sept. 12, 2023 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) today announced that is has published its fiscal year 2023 Environmental, Social, Governance (ESG) report .
  • "Our ESG report reflects our commitment to accountability and transparency to key stakeholders and details the progress we have made over the last twelve months," said Christopher Rossi, President & CEO.
  • Highlights from the report include:
    Reductions in Scope 1 and Scope 2 greenhouse gas emissions, energy consumption, water consumption and increase in waste recycling.
  • Kennametal also recognizes the importance of the United Nation's Sustainability Development Goals (SDG) and has aligned the SDGs with priority topics.

ForwardLane Launches EMERGE - Generative AI Platform to Supercharge New Gen of Financial Services Professionals

Retrieved on: 
Tuesday, August 8, 2023

Fully compliant, transparent, flexible, easily deployable and upgradable, the solution provides real-time answers, insights and analytics sourced from internal and external enterprise data.

Key Points: 
  • Fully compliant, transparent, flexible, easily deployable and upgradable, the solution provides real-time answers, insights and analytics sourced from internal and external enterprise data.
  • Following conversations with C-Suite executives and Data & Analytics teams in financial services firms, it became clear to ForwardLane that the complexity of deploying private, secure, and accurate generative AI is a big challenge and a large drain on resources.
  • EMERGE is an applied Generative AI solution for financial services that brings together the best functionalities of ForwardLane's ViGOR and privacy-friendly EMERGE-GPT.
  • It gives financial services firms the ability to rapidly activate their existing data and data science investments and deliver insights to their frontline advisory and sales professionals."

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

Retrieved on: 
Wednesday, July 5, 2023

Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively.

Key Points: 
  • Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively.
  • After taking open-label simufilam for 12 months, 76 patients with mild Alzheimer’s disease (MMSE 21-26) enrolled in the CMS and were randomized to receive either simufilam (N=40) or placebo (N=36) for 6 months.
  • Mild patients randomized to simufilam in the CMS showed no material decline in ADAS-Cog scores over 18 months as a group, indicating stable cognition.
  • In this small study of oral simufilam in patients with mild-to-moderate Alzheimer’s disease, the pre-specified cognitive endpoint showed a 38% decline in ADAS-Cog over six months in favor of simufilam, with good drug safety.

Jack Kent Cooke Foundation Announces New Grants Dedicated to College Access and Academic Excellence

Retrieved on: 
Wednesday, June 7, 2023

"These grants build on our nearly two decades of working alongside organizations focused on helping high-achieving students without financial resources pursue postsecondary education," said Seppy Basili, executive director of the Jack Kent Cooke Foundation.

Key Points: 
  • "These grants build on our nearly two decades of working alongside organizations focused on helping high-achieving students without financial resources pursue postsecondary education," said Seppy Basili, executive director of the Jack Kent Cooke Foundation.
  • Since 2001, the Cooke Foundation has focused its efforts to expand educational opportunities by supporting high-achieving students directly as well as grantmaking to organizations with a track record of helping students prepare for college.
  • In 2022, 100% of students that participated in Delaware College Scholars' intensive summer residential programming graduated high school and 98% of those students matriculated into college.
  • Students are able to earn college credit, gain exposure to actual college courses and faculty, and receive college advising.